Technology
Health
Biotechnology

Vanda Pharmaceuticals

$18.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.13 (0.71%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell VNDA and other stocks, options, ETFs, and crypto commission-free!

About

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Read More Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Employees
270
Headquarters
Washington, District of Columbia
Founded
2002
Market Cap
956.14M
Price-Earnings Ratio
39.23
Dividend Yield
0.00
Average Volume
748.50K
High Today
$18.60
Low Today
$18.25
Open Price
$18.28
Volume
178.12K
52 Week High
$33.44
52 Week Low
$13.88

Collections

Technology
Health
Biotechnology
Medical
US
North America

News

Yahoo FinanceMar 14

CLASS ACTION UPDATE for MU, STMP and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / March 14, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.

351
Yahoo FinanceMar 11

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MKL, VNDA and CTL

NEW YORK, NY / ACCESSWIRE / March 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies.

0
Guru FocusMar 7

Vanda (VNDA) Class Action Lawsuit: Bernstein Liebhard LLP Announces A Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. – VNDA

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Vanda Pharmaceuticals Inc.

61

Earnings

-$0.28
-$0.10
$0.08
$0.26
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.